secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000885725-24-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility
--------------------------------------------------------------------------------

- Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.
- Pegus brings 25+ years of clinical and business leadership; most recently partner at Morgan Health, formerly EVP at Walmart and CMO at Walgreens.
- Company amended its $2.75B revolving credit agreement, extending maturity to May 2029 for consenting lenders and adjusting the pricing grid.
- Reset EBITDA exclusion cap for restructuring charges to $500M since March 31, 2024 (previously December 31, 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/bsx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer